Dana-Dwek Children’s Hospital at Tel Aviv’s Ichilov medical center has begun treating children newly diagnosed with type 1 diabetes with a drug meant to preserve the function of insulin-producing beta cells in the pancreas, the first time the treatment has been offered in Israel.
The drug, Anti-Thymocyte Globulin (ATG, sold as Thymoglobulin), is given in the hospital’s pediatric day unit. It modulates the immune system and limits the autoimmune damage to pancreatic cells, offering a chance to keep the body producing its own insulin.
The effort was led by Prof. Yael Lebenthal and Dr. Erez Azulay of the Institute of Pediatric Endocrinology, Diabetes and Metabolism, together with the day unit and pharmacy staff.
More information is available on the Ichilov website.


